-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
When vaccines are close to mass production, vaccine vials, vaccine cold chains, and syringes have become resources for competition
.
After the emergency use of the new crown vaccine in the United Kingdom and the United States and other countries, China has recently begun to officially deploy large-scale key population vaccinations, and several well-known medical product manufacturers at home and abroad are busy expanding the production capacity of syringes
.
BD receives a total of 1 billion syringe orders
Becton, Dickinson and Company (BD), a world-renowned company in the production and sales of medical equipment and reagents, has received orders for syringes and needles for the new crown vaccine, totaling more than 1 billion syringes
.
At present, some orders are already being shipped
.
BD's syringe for the new crown vaccine
In addition to being fully prepared for the current COVID-19 vaccination, BD has also taken various measures to respond to the large-scale vaccination of the international community in the future:
1.
BD cooperates with the US government on a $70 million syringe production line project to further expand BD's manufacturing capacity in Nebraska, USA
.
2.
BD will invest approximately $1.
2 billion over four years to expand and upgrade its manufacturing capacity and technology for pre-filled syringes and drug delivery systems to cope with the growth in the number of injectable drugs and vaccines, while also increasing the number of pre-filled syringes used in the pandemic.
The ability to cope with the epidemic
.
3.
BD actively collaborates with medical technology associations and research groups to address the challenges of producing syringes, propose solutions and further technological innovations to support a more sustainable vaccine ecosystem
.
Not only is BD accelerating the production of syringes and needles, but it is also actively working closely with governments and multilateral organizations around the world to increase access to testing and patient care for COVID-19
.
The company has provided healthcare workers around the world with millions of products used to combat COVID-19, including nasopharyngeal swabs for influenza and COVID-19 testing, rapid molecular diagnostic tests on the BD MAX™ System, 15-minute point-of-care antigen testing on the BD Veritor™ Plus system, along with infusion pumps, infusion sets, and catheters
.
BD Biosciences instruments are also used by researchers around the world to understand the human immune response to the new coronavirus
.
Domestic manufacturers are busy expanding production capacity
Domestic manufacturers are busy expanding production capacityZhejiang Kangkang Medical Equipment Co.
, Ltd.
recently stated that the company's annual production capacity has reached about 250 million various types of syringes, about 800 million various types of injection and puncture needles, and about 80 million sets of various types of infusions.
, self-destruction, safety and other models and specifications
.
"But the current production capacity is not expected to meet the needs of domestic and foreign markets
.
" said the person in charge of Kangkang Medical
.
The small-volume syringes of 1ml and below produced by Kangkang Medical can be used for vaccine injection.
At present, the company is expanding the production capacity of syringes and expects the annual output of various syringes to reach 1 billion
.
Syringes of various specifications of Zhejiang Kangkang Medical Equipment Co.
, Ltd.
The person in charge of Kangkang Medical said a few days ago: "Most of the current intentional orders come from the international market, and the volume of foreign orders is very obvious.
Previously, 1 to 2 million orders were received, and now tens of millions of orders have been received
.
"
Orders for small-volume syringes almost filled the company's capacity
.
Kangkang Medical is currently adding mold equipment, and it is expected that the production capacity can increase to 7 to 8 times from February
.
Jiangxi Sanxin Medical also stated on December 25 that the company's vaccine syringes, self-destructing syringes and other related products have received orders, but the current production capacity is sufficient
.
In addition, the company's injection product production equipment has a high degree of automation.
If market demand further increases, product production capacity can be rapidly increased
.
The person in charge of Sanxin Medical stated that the injection products have passed the EU CE certification, the US FDA (510K) marketing authorization and the World Health Organization (WHO) PQS procurement qualification, and can be exported to relevant countries and regions
.
